Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 6Mouth Neoplasms 4Laryngeal Neoplasms 4Hypopharyngeal Neoplasms 4Carcinoma 4Oropharyngeal Neoplasms 3Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoid Interstitial Pneumonia 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 27Fluorouracil 23Cetuximab 23Leucovorin 22Bevacizumab 21Nivolumab 16Capecitabine 16Irinotecan 15pembrolizumab 12Magnetic Resonance Spectroscopy 11Specimen Handling 10encorafenib 8Folfox protocol 7trifluridine tipiracil drug combination 6Ipilimumab 6Exercise 6fludarabine 5cemiplimab 5Trastuzumab 5Gemcitabine 5Cyclophosphamide 5Cisplatin 5Blood Specimen Collection 5Biopsy 5regorafenib 4pertuzumab 4adagrasib 4Trifluridine 4Surgical Procedures, Operative 4Pemetrexed 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × (225)Ac-DOTA-c(RGDyK) × 1 year × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡